## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.9% in lower entry zone (3.0-6.0%), top quartile (87th pct) cross-sectional ranking. Short-term MRS_5 (2.2%) confirms momentum alignment. Strong momentum (+4.2% 5-day acceleration). Outperforming sector by 3.9%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($477.34)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Texas Permanent School Fund Corp Increases Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251215T130907 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 7.2% in the second quarter, valuing its holdings at approximately $14.77 million. This comes despite recent insider selling by executives. Analysts maintain a "Moderate Buy" rating for United Therapeutics with an average price target of $505.00, reflecting confidence in the biotechnology company's performance and future prospects.

**2. Thrivent Financial for Lutherans Has $53.30 Million Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251215T120907 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans recently reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 9.8%, now holding 185,477 shares valued at $53.30 million. Insider selling has also been noted, with CEO Martine Rothblatt selling shares, though institutional investors still hold a significant portion of the company. United Therapeutics reported Q3 EPS of $7.16, exceeding estimates, and has a "Moderate Buy" consensus rating with a $505 price target.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($10.81M) |
| Sells | 76 ($45.40M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $45M sold (76 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +4.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.6x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($45.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.6B |
| Beta | 0.86 |
| 52W Range | $266.98 - $502.77 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.6 |
| Current P/E | 18.5 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.3% to 3.9% (+4.2% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 87th percentile. MRS_5 at 2.2% confirms short-term momentum alignment. Outperforming sector by 3.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.88% (CS: 87) | Strong |
| RSI_14 | 68.4 | Neutral |
| MACD Histogram | 0.28 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.089x | Above |
| vs SMA200 | 1.408x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $500.00
- **Stop Loss:** $477.34 (4.5% risk)
- **Target:** $533.99 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 44
- **Position Value:** $22,000.00
- **Portfolio %:** 22.00%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*